Expression of DNA damage response proteins in gastric cancer: Comprehensive protein profiling and histological analysis

Arai,Hiroki; Wada,Ryuichi; Ishino,Kousuke; Kudo,Mitsuhiro; Uchida,Eiji; Naito,Zenya

doi:10.3892/ijo.2018.4238

Expression of DNA damage response proteins in gastric cancer: Comprehensive protein profiling and histological analysis

Authors:
- Hiroki Arai
- Ryuichi Wada
- Kousuke Ishino
- Mitsuhiro Kudo
- Eiji Uchida
- Zenya Naito
View Affiliations

Affiliations: Department of Integrated Diagnostic Pathology, Nippon Medical School, Tokyo 113-8602, Japan, Department of Gastrointestinal Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo 113-8602, Japan
Published online on: January 5, 2018 https://doi.org/10.3892/ijo.2018.4238
Pages: 978-988

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer is the third major cause of cancer-related mortality in Japan. The aim of this study was to identify a factor implicated in the biology of gastric cancer by comprehensive protein profiling. Protein profiling was carried out by liquid chromatography-tandem mass spectrometry, using formalin-fixed paraffin-embedded specimens of 17 gastric cancer cases. Pathway analysis and orthogonal partial least square-discriminant analysis suggested the significant expression of ribonucleoproteins, heterogeneous nuclear ribonucleoproteins, interleukin binding factor 2 (ILF2), KU70 and KU80, which are involved in DNA damage response (DDR). Thus, the expression and phosphorylation levels of KU70, ILF2, CHK1 and CHK2 were examined by immunohistochemistry in 42 cases of gastric cancer. The expressions of ILF2 and CHK1 were unaffected in all cases. The expression and phosphorylation of CHK2 were absent in 2 cases. Despite the expression of proteins, the phosphorylation of KU70 and CHK2 appeared to be impaired in 1 and 4 cases, respectively. In 7 out of 42 cases (17%), DDR appeared to be impaired. Recurrence was noted in 2 out of these 7 cases (29%), whereas the recurrence was noted in 2 out of the remaining 35 cases (6%). The expression levels of KU70, ILF2, CHK1, CHK2 and TP53 were further examined in 4 gastric cancer cell lines. The expression and phosphorylation levels following exposure to ultraviolet radiation were abnormal in the 3 cell lines. The normal consecutive phosphorylation of CHK1 and CHK2, the upregulation of TP53 and an increase in apoptotic cell death following exposure to ultraviolet radiation was detected only in one cell line, suggesting that the preserved functions of DDR and TP53 are necessary for the determination of cell fate. It is thus suggested that DDR plays an important role in the pathobiology of gastric cancers.

View Figures

View References

1	Kodera Y: The current state of stomach cancer surgery in the world. Jpn J Clin Oncol. 46:1062–1071. 2016. View Article : Google Scholar
2	Shitara K: Chemotherapy for advanced gastric cancer: Future perspective in Japan. Gastric Cancer. 20(Suppl 1): 102–110. 2017. View Article : Google Scholar
3	Eke I, Makinde AY, Aryankalayil MJ, Ahmed MM and Coleman CN: Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine. Cancer Lett. 382:118–126. 2016. View Article : Google Scholar : PubMed/NCBI
4	Pan L, Aguilar HA, Wang L, Iliuk A and Tao WA: Three-dimensionally functionalized reverse phase glycoprotein array for cancer biomarker discovery and validation. J Am Chem Soc. 138:15311–15314. 2016. View Article : Google Scholar : PubMed/NCBI
5	Boussioutas A, Li H, Liu J, Waring P, Lade S, Holloway AJ, Taupin D, Gorringe K, Haviv I, Desmond PV, et al: Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res. 63:2569–2577. 2003.PubMed/NCBI
6	Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, Hinoue T, Laird PW, Curtis C, Shen H, et al Cancer Genome Atlas Research Network: Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513:202–209. 2014. View Article : Google Scholar :
7	Sousa JF, Ham AJ, Whitwell C, Nam KT, Lee HJ, Yang HK, Kim WH, Zhang B, Li M, LaFleur B, et al: Proteomic profiling of paraffin-embedded samples identifies metaplasia-specific and early-stage gastric cancer biomarkers. Am J Pathol. 181:1560–1572. 2012. View Article : Google Scholar : PubMed/NCBI
8	Sunakawa Y and Lenz HJ: Molecular classification of gastric adenocarcinoma: Translating new insights from the cancer genome atlas research network. Curr Treat Options Oncol. 16:172015. View Article : Google Scholar : PubMed/NCBI
9	Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, et al: Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 141:476–485. 2011. View Article : Google Scholar : PubMed/NCBI
10	Jackson SP and Bartek J: The DNA-damage response in human biology and disease. Nature. 461:1071–1078. 2009. View Article : Google Scholar : PubMed/NCBI
11	Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 64:31–49. 1965. View Article : Google Scholar : PubMed/NCBI
12	Blanpain C, Mohrin M, Sotiropoulou PA and Passegué E: DNA-damage response in tissue-specific and cancer stem cells. Cell Stem Cell. 8:16–29. 2011. View Article : Google Scholar : PubMed/NCBI
13	Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D'Anca M, Storti P, Samur MK, Ganan-Gomez I, Fulciniti MT, et al: ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma. Cancer Cell. 32:88–100. e1062017. View Article : Google Scholar : PubMed/NCBI
14	Kai M: Roles of RNA-binding proteins in DNA damage response. Int J Mol Sci. 17:3102016. View Article : Google Scholar : PubMed/NCBI
15	Yokozaki H: Molecular characteristics of eight gastric cancer cell lines established in Japan. Pathol Int. 50:767–777. 2000. View Article : Google Scholar : PubMed/NCBI
16	Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, Chan TL, Kan Z, Chan AS, Tsui WY, et al: Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 43:1219–1223. 2011. View Article : Google Scholar : PubMed/NCBI
17	Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, et al: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 434:864–870. 2005. View Article : Google Scholar : PubMed/NCBI
18	Halazonetis TD, Gorgoulis VG and Bartek J: An oncogene-induced DNA damage model for cancer development. Science. 319:1352–1355. 2008. View Article : Google Scholar : PubMed/NCBI
19	Poehlmann A and Roessner A: Importance of DNA damage checkpoints in the pathogenesis of human cancers. Pathol Res Pract. 206:591–601. 2010. View Article : Google Scholar : PubMed/NCBI
20	Shigeishi H, Yokozaki H, Oue N, Kuniyasu H, Kondo T, Ishikawa T and Yasui W: Increased expression of CHK2 in human gastric carcinomas harboring p53 mutations. Int J Cancer. 99:58–62. 2002. View Article : Google Scholar : PubMed/NCBI
21	Lee HE, Han N, Kim MA, Lee HS, Yang HK, Lee BL and Kim WH: DNA damage response-related proteins in gastric cancer: ATM, Chk2 and p53 expression and their prognostic value. Pathobiology. 81:25–35. 2014. View Article : Google Scholar
22	Matsunobu T, Ishiwata T, Yoshino M, Watanabe M, Kudo M, Matsumoto K, Tokunaga A, Tajiri T and Naito Z: Expression of keratinocyte growth factor receptor correlates with expansive growth and early stage of gastric cancer. Int J Oncol. 28:307–314. 2006.PubMed/NCBI
23	Xu W, Wang S, Chen Q, Zhang Y, Ni P, Wu X, Zhang J, Qiang F, Li A, Røe OD, et al: TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer. Cell Death Dis. 5:e10552014. View Article : Google Scholar : PubMed/NCBI
24	Ronchetti L, Melucci E, De Nicola F, Goeman F, Casini B, Sperati F, Pallocca M, Terrenato I, Pizzuti L, Vici P, et al: DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. Int J Cancer. 140:2587–2595. 2017. View Article : Google Scholar : PubMed/NCBI
25	Gutiérrez-González A, Belda-Iniesta C, Bargiela-Iparraguirre J, Dominguez G, García Alfonso P, Perona R and Sanchez-Perez I: Targeting Chk2 improves gastric cancer chemotherapy by impairing DNA damage repair. Apoptosis. 18:347–360. 2013. View Article : Google Scholar